Mirati Therapeutics (United States)

Recent papers from Mirati Therapeutics (United States)

1. Combination of KRASG12C targeted adagrasib with anti-PD-1 immune-checkpoint inhibitor to improve overall survival and prevent recurrence in preclinical models of brain metastasisNeuro-Oncology Advances · 2026
2. Abstract 2644: Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors.Cancer Research · 2026
3. Reconstructing Liver Fibrosis: 3D Human Models, Microbiome Interfaces, and Therapeutic InnovationCurrent Issues in Molecular Biology · 2026
4. Outcome strategies for clinical trials in Neuropaediatric rare diseasesNeuroscience Applied · 2026
5. Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myelomaBlood · 2025
6. Methodological challenges in outcomes research for early-trials for implementation of new therapies in neuropediatric rare diseasesOrphanet Journal of Rare Diseases · 2025
7. Molecular Magnetic Resonance Imaging of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma Lesions and Response to KRASG12D Inhibitor TreatmentCancer Research · 2025
8. Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database AnalysisClinical Lung Cancer · 2025
9. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP -Deleted KRAS -Mutant Pancreatic CancerCancer Research · 2025
10. Population-adjusted unanchored indirect comparisons of cancer therapies with borrowing of pan-tumor informationStatistical Methods in Medical Research · 2025
11. Development of a Solid Phase Extraction Cartridge‐Based Analytical Method for Determination of Free Drug in Nanoliposomal Oncology Drug FormulationsJournal of Separation Science · 2025
12. Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2AActa Neuropathologica Communications · 2025
13. Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitisJournal of Crohn s and Colitis · 2025
14. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialClinical Cancer Research · 2025
15. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialNature Communications · 2025
16. Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJournal of Crohn s and Colitis · 2025
17. Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug InteractionsClinical Pharmacology & Therapeutics · 2024
18. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyFuture Oncology · 2024
19. Exploration of Cryptic Pockets Using Enhanced Sampling Along Normal Modes: A Case Study of KRAS G12DJournal of Chemical Information and Modeling · 2024
20. Abstract C077: Functional Dissection of the Highly Plastic Basal Cell State in Pancreatic CancerCancer Research · 2024